Here you will find current external funding opportunities available for innovation and research projects.

If you are aware of funding oportunities that are not listed please email the detail to stees.ideas@nhs.net and they will be added to the website.

 

Audience of the future: design foundations

Innovate UK, as part of UK Research and Innovation, will invest up to £1 million to fund early-stage, human-centred design projects through the Industrial Strategy Challenge Fund (ISCF). These will seek to understand customer needs and create new or better ideas for:

immersive audience experiences across the creative industries
products or services used to create, deliver and experience immersive content across the creative industries

Projects must use established human-centred design principles (such as the Design Council’s ‘double diamond’ process).

Immersive experiences blur the line between the physical and simulated world. They use virtual, mixed, and augmented reality technologies, haptics and other sensory interfaces coupled with data.

This competition is for early-stage projects that use customer research to generate ideas that meet customer needs. Fast, low-cost prototyping and user testing of those ideas is also within scope. Projects should deliver well-defined, user-validated ideas ready for further technical research and development (R&D).

This is part of the Industrial Strategy Challenge Fund’s Audience of the Future programme. Successful applicants will have an opportunity to apply for later stage R&D funding from this programme in 2019.

Deadline: Wednesday 4th July 2018 at 1200hrs

Further information can be found here.

 

Precision medicine technologies: shaping the future

Successful applicants will be able to analyse and evaluate the commercial potential of a technology, identify the requirements and resources needed to bring it to market and establish the prospects of success in the target market.

You must explain clearly how your proposed technology will improve precision medicine. It must make it easier for medical professionals to choose an appropriate patient treatment. We want you to justify why the proposed technology or service will help with the selection of the most appropriate treatment for the patient.

You can apply to carry out either:

  • a business-led feasibility study
  • collaborative research and development

We are looking to fund a portfolio of projects, across a variety of technologies, markets, medicine classes, and technological maturities. These may include feasibility studies, industrial research projects or experimental development projects.

Deadline: Wednesday 11th July 2018 at 1200hrs

Further information can be found here.

 

Open programme funding competition round 1

To be in scope, a proposal must demonstrate:

  • a clear game-changing and/or disruptive innovative idea leading to novel, new products, processes or services that are significantly ahead of others in the field
  • a strong and deliverable business plan that addresses (and documents) market potential and needs
  • a team, business arrangement or working structure with the necessary skills and experience to run and complete the project successfully and on time
  • awareness of all the main risks the project will face with realistic management, mitigation and impact minimisation plans for each
  • sound, practical financial plans and timelines that represent good value for money
  • a clear, evidence based plan to deliver significant economic impact, return on investment (ROI) and growth through commercialisation, as soon as possible following project completion

Where possible, all projects should take customer and user needs into account to deliver more desirable and useful solutions.

Priority will be given to proposals that are likely to lead to sustainable gains in productivity or access to new overseas markets through export led business growth.

As an integral part of the Industrial Strategy Challenge Fund (ISCF), this competition is designed to overcome barriers to the best cutting edge, game changing innovations becoming a successful commercial reality, with considerable economic impact and/or resulting in significant, sustainable business growth.

We provide funding for innovation-based enterprises. Such enterprises should demonstrate their readiness to deliver a project leading to new, highly innovative processes, products or services.

Competition demand is likely to be very high. Only those proposals with clear cutting-edge, game changing innovation which demonstrate the most robust business plans and highest potential for return on investment and impact are likely to be funded.

You will be competing against global standard proposals for some of the most advanced, cutting edge innovations in the UK and beyond. You need to ensure this is the right competition for your business model, and that your proposal is right for Open.

Deadline: Wednesday 11th July 2018 at 1200hrs

Further information can be found here.

 

18/07 - Rural Health

Which interventions are effective* in improving health and reducing health inequalities for rural** populations? Rural areas have diverse characteristics and populations and this is reflected in their health profiles and issues. Overall, health outcomes tend to be better in rural areas than urban areas in the UK, with higher life expectancy and lower rates of premature deaths, and greater proportions of people reporting themselves to be in good health. However, rural areas have particular challenges that can contribute to poorer health outcomes, and these may affect some locations and some populations disproportionately.

Deadline: Tuesday 24th July 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/06 Enabling people to live well with dementia through interventions in a community setting

Which interventions within a community environment (physical and social) make it easier for people with dementia to maintain quality of life and remain living in their community for longer? Effective design features for producing dementia friendly environments at both the housing and neighbourhood levels, can help enable a person with dementia to maintain quality of life, continue normal routines and activities, and potentially enable them to remain at home for longer, and delay the need for a move into residential accommodation.

Deadline: Tuesday 24th July 2018 at 1300hrs

Further information can be found here.

 

UK Research and Innovation strength in places fund

Project consortia must be based within the project’s geographical area and have the support of local civic leadership. Projects can be led by either a UK based business or a UK publicly funded research organisation. This first competition stage is an expression of interest (EoI). Consortia will set out plans for large collaborative proposals. Following assessment, successful EoIs will be selected to receive up to £50,000 in ‘seedcorn funding’ to further develop a proposal for a full stage project.

Deadline: Wednesday 25th July 2018 at 1200hrs

Further information can be found here.

 

NIHR 18/60 Public Health Research Programme: Researcher-led

The Public Health Research Programme are accepting stage 1 applications to their researcher-led workstream researcher-led; including complex health and care needs in older people highlight notice, brain tumour highlight notice, and London Devolution highlight notice.

Deadline: Tuesday 31st July 2018 at 1300hrs

Further information can be found here.

 

Audience of the future: demonstrators

Innovate UK, as part of UK Research and Innovation, will invest up to £16 million in 4 large scale creative industries demonstrator projects through the Industrial Strategy Challenge Fund (ISCF). This is part of the Audience of the Future (AotF) programme.

This competition aims to explore future global, mass market, commercial opportunities in the creative industries. Primarily this will be through pre-commercial collaboration at scale.

You must demonstrate you can significantly improve on the current state of the art in your field. Proposals should describe the: 

  • audience proposition you will create
  • innovation approach you will take
  • partners you will need to bring together
  • route to your audience

Proposals must include access to globally recognised intellectual property (IP) and reach an audience of 100,000 people. They must detail how the project will generate consumer insight at scale.

There will be 2 stages within the competition: a written application followed by an interview.

Projects must be business-led and carried out in collaboration with organisations from relevant sectors.

Deadline: Wednesday 1st August 2018 at 1200hrs

Further information can be found here.

 

NIHR 18/37 Repair of digital nerve injury

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 1st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/24 Early reoperation for patients with residual glioblastoma

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic

Deadline: Wednesday 1st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/25 Microstructural scaffold insertion following microfracture for chondral knee defects

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic

Deadline: Wednesday 1st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/26 Surgical management of pressure ulcers

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic

Deadline: Wednesday 1st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/27 Alternative bisphosphonate regimens for the prevention of osteoporotic fracture in adults

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic

Deadline: Wednesday 1st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/28 Paediatric Wrist Fractures

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic

Deadline: Wednesday 1st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/29 Preventing job loss in people with long term physical health conditions

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.  The UK NIHR and the Australian National Health and Medical Research Council (NHMRC) are collaborating on this research priority and will consider joint funding for any collaborative research proposals submitted to this brief. Applications which include a research collaboration between UK and Australian institutions are most welcome. Please refer to the supplementary guidance for additional requirements related to NIHR/NHMRC collaborative applications. It is important to note that whilst collaborative applications are invited, applications from UK institutions without an Australian collaborative element are also welcome for consideration and will be treated equally by the Board.

Deadline: Wednesday 1st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/30 Hysteroscopic removal of retained placenta

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 1st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/31 Discontinuation of growth hormone treatment in pubertal children

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 1st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/32 Management of orthostatic hypotension

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 1st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/33 Valuing the benefits and harms of antenatal and new born screening programmes in the UK

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 1st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/34 Routinely used interventions for improving attachment in infants and young children

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 1st August 2018 at 1300hrs

Further information can be found here.

 

18/56 Neurodegenerative Disorders

The Efficacy and Mechanism Evaluation Programme is accepting stage 1 applications to their commissioned workstream.

Deadline: Tuesday 21st August 2018 at 1300hrs

Further information can be found here.

 

18/55 Improving Safety and Efficacy Through Targeted Drug Delivery

The Efficacy and Mechanism Evaluation Programme is accepting stage 1 applications to their commissioned workstream.

Deadline: Tuesday 21st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/58 Efficacy and Mechanism Evaluation Programme - Researcher Led

The Efficacy and Mechanism Evaluation Programme is accepting stage 1 applications to their researcher-led workstream:

18/58 Researcher-led (including complex health and care needs in older people and brain tumour highlight notices)

Deadline: Tuesday 21st August 2018 at 1300hrs

Further information can be found here.

 

18/57 Type 2 Diabetes

The Efficacy and Mechanism Evaluation Programme is accepting stage 1 applications to their commissioned workstream.

Deadline: Tuesday 21st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/59 Mechanisms of Action of Health Interventions

The Efficacy and Mechanism Evaluation Programme is accepting stage 2 applications to their commissioned workstream.

Deadline: Tuesday 21st August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/66 Health Technology Assessment Programme researcher-led (primary research)

The Health Technology Assessment Programme is accepting stage 1 applications to their researcher-led workstream, 18/66 - Researcher-led primary research (including brain tumours, and complex health and care needs in older people highlight notices)

Deadline: Wednesday 29th August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/65 Health Technology Assessment Programme researcher-led (evidence synthesis)

The Health Technology Assessment Programme is accepting evidence synthesis stage 1 applications to their researcher-led workstream, 17/148 - Researcher-led evidence synthesis (including brain tumours, and complex health and care needs in older people highlight notices)

Deadline: Wednesday 29th August 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/74 Health Services and Delivery Research Programme researcher-led (evidence synthesis)

The Health Services and Delivery Research (HS&DR) Programme is accepting stage 2 evidence synthesis applications to their researcher-led workstream.

Deadline: Thursday 6th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/73 Health Services and Delivery Research Programme researcher-led (standard)

The Health Services and Delivery Research (HS&DR) Programme are accepting stage 1 applications to their researcher-led workstream.

Deadline: Thursday 6th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/40 Short-term use of benzodiazepines for the acute management of acute low back pain

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 19th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/39 Earlier active management of ovarian hyperstimulation syndrome

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 19th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/43 Rotation of the fetal head at full cervical dilatation

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 19th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/41 Clinical and cost effectiveness of alternative urinary catheter design

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 19th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/52 Management of isolated or incidental subsegmental pulmonary embolism

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 19th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/44 Pre Hospital Pain Management

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 19th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/45 Proton pump inhibitor therapy for refractory gastro-oesophageal reflux symptoms

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 26th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/42 Cystic Fibrosis

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 26th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/47 Outpatient cervical ripening for induction of labour

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 26th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/46 Pharmacological management of post-traumatic seizures

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 26th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/48 Radiotherapy in first-line treatment of diffuse large B-cell lymphoma

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 26th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/49 Radiofrequency denervation for low back pain

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 26th September 2018 at 1300hrs

Further information can be found here.

 

NIHR 18/51 Extended duration haemodialysis

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic.

Deadline: Wednesday 26th September 2018 at 1300hrs

Further information can be found here.

H2020: Systems approaches for the discovery of combinatorial therapies for complex disorders - SC1-BHC-02-2019

Specific Challenge: Many complex disorders pose a challenge to identify the most effective therapeutic interventions because current therapies often target specific aspects of a disease, without achieving complete control or the best possible results for patients. Due to the multiple causes of such diseases and the heterogeneity between patients, approaches directed at single targets have had limited efficacy, overlooking important factors involved in disease pathophysiology. Hence, a promising therapeutic approach to meet this challenge is to combine different therapies, while increasing therapeutic efficacy in a cost-effective manner.

ScopeResearch should aim to understand at systems level the pathophysiology of a disorder in groups of patients responding well or poorly to particular therapies and further develop combinatorial therapies tailored to the needs of individuals or stratified patient groups.

Projects should focus on already available and/or authorised therapies and have access to standardized biobank samples derived from retrospective or currently running clinical studies. These patient samples should be re-analysed with modern high-throughput technologies. The existing and newly produced data should be integrated using systems approaches, which could combine sub-cellular/cellular and/or organ level in-silico models and network analysis as appropriate, and used to build more sophisticated computational frameworks to predict patient responses to combinatorial therapies. These predictions should be validated in pre-clinical and clinical studies taking into account sex and gender differences. Funding of late stage clinical trials is not within the scope of this topic.

Applicants should include a thorough data management plan for transnational data sharing to enable the computational analysis and it is strongly recommended to adhere to the state-of-the-art international standards and to the general concepts of the FAIR principles.

The topic invites proposals in complex disorders of high prevalence and of a high economic burden (rare diseases are excluded). SME participation is strongly encouraged.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:

  • New concepts of combinatorial therapies for complex disorders tailored to the needs of individuals or stratified patient groups.
  • Improved efficacy and take-up in the clinical setting in comparison to established therapeutic interventions.
  • Enable the development of personalised medicine.
  • Increased research & innovation opportunities in this industry intensive field, particularly for SMEs.

Delegation Exception Footnote:

https://www.nature.com/scitable/topicpage/complex-diseases-research-and-applications-748

Deadline: Tuesday 2nd October at 1700 hrs (CET)

Further information can be found here.

H2020: Understanding causative mechanisms in co- and multi-morbidities - SC1-BHC-01-2019

Specific ChallengeThe increasing number of individuals with co-and multimorbidities poses an urgent need to improve management of patients with multiple co-existing diseases. A better understanding of their causative mechanisms is needed to develop early diagnosis, efficient prevention and monitoring, and better treatments adapted to co- and multimorbid patients throughout their life course. Furthermore, there are many different etiological models of comorbid conditions (e.g., direct causation model or a consequence of treatment). In this context, capturing and measuring patient's complexity in the context of co- and multimorbidities is crucial for adequate management of these conditions and requires innovative approaches.

ScopeProposals should identify and validate causative mechanisms (e.g. molecular, genetic, correlative, drug-drug interaction) combining mental and physical disorders through the integration of basic, pre-clinical and/or clinical research. Applicants should prove the relevance of the identified mechanisms for co-morbid development. Where pertinent, development of biomarkers and other technologies for diagnosis and monitoring of comorbid conditions in patients is encouraged. A purposeful exploitation of existing data, biobanks, registries and cohorts is expected, but does not exclude generation of new data. Sex and gender aspects, age, socio-economic, lifestyle and behavioural factors and any other non-health related individual attributes should be taken into consideration. SME participation is strongly encouraged.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:

  • New directions for clinical research to improve prevention, diagnosis, prognosis, therapy development, and management of co- and multimorbidities.
  • Whenever relevant identified biomarkers for more accurate and earlier diagnosis, prognosis as well as monitoring of patients' condition.

Cross-cutting PrioritiesSocio-economic science and humanities and Gender

  • Clinical trials are excluded
  • Including any national, EU or international resource or infrastructure if appropriate.

Deadline: Tuesday 2nd October at 1700 hrs (CET)

Further information can be found here.

H2020:Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases- SC1-BHC-14-2019

Specific ChallengeDespite major advances in development of new drugs and vaccines against infectious diseases, many of the therapies and preventive measures do not result in the expected favourable health outcomes for various reasons. The pathogen might be resistant to the treatment, or a required immune response might not be provoked to contain the infection; the used drug might not reach the pathogen, or the pathogen might escape the host defence mechanisms. In addition, each individual might be responding differently to the intervention, making it difficult to make one intervention fit all patients. A promising avenue to overcome treatment failure in infectious diseases is to develop novel therapeutic or preventive approaches on the basis of specific factors identified in the host or the host-pathogen interaction. This approach provides the basis for stratification of individuals based on these characteristics and tailor the treatment or the preventive measure accordingly.

ScopeProposals should test emerging concepts in drug and/or vaccine development in order to address the problem of antimicrobial drug resistance and to optimize therapeutic, curative or preventive measures against infectious diseases of major concern for Europe. Proposals should capitalize on knowledge of the role of host factors, immune-modulators or of host-pathogen interactions influencing disease outcome that can be utilized to strengthen the response to treatment or prevention measures. This should lead to new enhanced therapies, cures and/or preventive measures. Differences in factors such as age, gender and genetic variation among the human population should be taken into consideration.

The proposals should focus on late pre-clinical and/or clinical research, supporting proof of concept and selecting relevant biomarkers for clinical validation. They should take advantage of existing or newly established cohorts to help identify factors for predicting the course of the disease and its response to the intervention in stratified patients.

The downstream constraints for the uptake of the intervention by national health systems should be taken into account. The suitability, acceptability and adaptability of the interventions to be developed should be addressed and assessed for different population groups and will thus require expertise from the social sciences and the humanities.

The Commission considers that proposals requesting a contribution from the EU of between EUR 6 and 10 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:

  • Increase Europe's capacity to control infectious diseases.

  • Enriched product development pipelines with novel, potentially more effective, targeted treatments, cures and/or preventive measures for infectious diseases and/or validated biomarkers with potential for rapid uptake into clinical practice.

  • Reduced burden of major infectious diseases.

  • Contribute to the achievement of the European One Health Action Plan against Antimicrobial Resistance.

  • Contribute to the achievement of the Sustainable Development Goal 3, ensure health and well-being for all, at every stage of life.

Deadline: Tuesday 2nd October 2018 at 1700 hrs (CET)

Further information can be found here.

H2020: Implementation research for Maternal and Child Health- SC1-BHC-19-2019

Specific Challenge:Each year, an estimated 213 million women become pregnant and 140 million newborn babies are delivered. However, many of the women and infants receive no appropriate care or care that is below evidence-based standards; others suffer from over-medicalisation. Access to quality care, during and after pregnancy, is essential to ensure good maternal health and the favourable early development of the child.

The gap between countries with the lowest and highest maternal mortality rates has doubled between 1990 and 2013 and huge differences exist within countries in Europe and globally. The burden of maternal mortality in both contexts falls disproportionately on the most vulnerable groups of women and girls: Every day approximately 830 women die from preventable causes related to pregnancy and childbirth; 99% of maternal deaths occur in developing countries.

Although there is a consolidated evidence base of what works in improving maternal and newborn health, the "knowledge-do" gap has not been bridged and evidence based guidelines are insufficiently implemented or integrated in routine training and service provision. Therefore, more and better targeted implementation research is needed.

ScopeProposals should focus on implementation research for improving maternal and child health with a focus on the first '1000 days' from pregnancy until two years of age. This research can take place in either high income countries or low and middle income countries, or in a combination thereof.

The implementation research in the first 1000 days may cover:

  • new or improved health service delivery interventions that strengthen maternal and child health; and/or

  • the scaling up and/or adapting of existing evidence-based interventions to new contexts.

Neither pre-clinical research nor clinical trials in the context of product development are within the scope of this call.

The research should take into account the specificities of different contexts and situations. The research should be integrated from different perspectives, e.g. recognising the interdependent relationship between mother and child; addressing prevention, health promotion and treatment; allowing for the specific needs of vulnerable groups (e.g. preterm infants, adolescents, migrants); addressing different concurrent pathologies; avoiding the creation of parallel or vertical programmes, etc;. Research may cover physical and/or mental health, as well as communicable and non-communicable diseases. The integration of social sciences including gender analysis and the use of mixed methods research is strongly encouraged. In addition, particular attention should be given to equity issues.

The interventions should build on but may go beyond existing state-of-the art knowledge on biological, psychological and social determinants of maternal and child health. Research is expected to be carried out in continuous partnership, in particular with the end-users, i.e. the concerned women, the fathers, and their community, in addition to policy makers, politicians, and the media, to ensure that evidence can be translated into policy and practice.

The Commission considers that proposals requesting an EU contribution between EUR 2 to 4 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact

  • Research-supported solutions to maternal and child health challenges.

  • Providing evidence of successful and/or innovative approaches for bridging the ''knowledge-do'' gap in improving maternal and child health.

  • Better understanding of scaling-up processes with regard to different contexts and resource requirements.

  • Contribution to the achievement of SDGs 2 on improved nutrition (target 2), Goal 3 on health (targets 1 and 2 on maternal and child health) and Goal 5 on gender equality (targets 1 and 6) and Goal 10 (on reducing inequality within and between countries).

Deadline: Tuesday 2nd October 2018 at 1700 hrs (CET)

Further information can be found here.

 

H2020: Demonstration pilots for implementation of personalised medicine in healthcare- SC1-BHC-25-2019

Specific Challenge: Personalised medicine (PM) has the potential to respond to, among others, the increasing burden of co-morbidities and thus enhance the sustainability of healthcare systems. With the increasing number of scientific approaches available, it is crucial to demonstrate the benefit of large scale deployment of personalised medicine to citizens and healthcare systems. This was also one of the conclusions of the Personalised Medicine Conference 2016.

(http://ec.europa.eu/research/conferences/2016/permed2016/index.cfm).

ScopeThe pilot projects should demonstrate the benefit for individuals as well as the implementability and economic viability of personalised medicine approaches in real life healthcare settings. The pilots should be tailored to the needs of citizens, making use of a wide variety of data and proposing prediction, prevention or treatment solutions, focussing on diseases with high burden to society (taking due account of sex/gender differences) and including multi-morbidity conditions if relevant. The use of big data approaches and high performance computing is encouraged. Applicants should ensure coordination with national, regional or local authorities engaging in healthcare environments and should aim at linking different institutions (hospitals, other healthcare facilities, public health authorities, payers etc.). The pilot projects should engage partners in regions or cities having adopted or that are in advanced planning for introducing PM approaches. Patient representatives as well as partners from countries that are in the process of upgrading their healthcare systems should be involved, ensuring a wide European dimension. Applicants should address the health economic, ethical, legal and societal aspects of the proposed action. Taking into account the advances already achieved for PM approaches in cancer and rare diseases, projects with primary focus on these diseases are excluded from the scope of this topic.

The Commission considers that proposals requesting a contribution from the EU of between EUR 18 and EUR 20 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact

  • Evidence for a PM-based model of care that can be used as a basis for the delivery of new ways of care organisation.

  • Demonstration of the viability and feasibility of PM approaches in real-life settings and at a large scale, exemplifying potential for savings in overall healthcare costs.

  • Widening of PM approaches to include diseases other than cancer and rare diseases.

  • Linking of different actors for healthcare, economy, lifestyle, healthy living and regulation, making use of the multitude of data available.

Deadline: Tuesday 2nd October 2018 at 1700hrs (CET)

Further information can be found here.

H2020: Regenerative medicine: from new insights to new applications - SC1-BHC-07-2019

Specific ChallengeRegenerative medicine offers hope for untreatable disease and the ageing population, improved quality of life and reduced medical costs. However, so far, regenerative medicine has not yet proved itself in the clinic beyond rare diseases or conditions of limited public health importance. With recent scientific discoveries opening up new approaches to regenerative medicine, the challenge is to use these to extend the regenerative approach to major diseases and conditions.

ScopeRegenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function. Projects should focus on innovative translational research to develop regenerative processes towards the ultimate clinical goal of addressing unmet clinical needs of large patient groups. Proposals should be based on new approaches such as genome editing or gene therapy, transdifferentiation or in vivo reprogramming, cell therapy and transplantation, 3D bioprinting, organoids or use of combined products (non-exhaustive list for illustrative purposes only). In all cases, proposals should explain in what way their approach is regenerative. Research on improved methods of tissue and organ transplantation is included on the condition that there is a clear regenerative step in the process. The project may focus on any step(s) on the innovation chain, from early testing and characterization of regenerative mechanisms to preclinical research, proof of concept or clinical trial. Sex and gender differences should be investigated, where relevant. Projects should include a section on the proposed therapy's exploitation potential, regulatory and commercialisation strategy and how it would be made available and delivered to patients.

The Commission considers that proposals requesting a contribution from the EU of between EUR 6 and 8 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact

  • Potential new regenerative therapies to address unmet clinical needs of large patient groups identified
  • Europe's position in translational regenerative medicine strengthened
  • New therapies for major human diseases and conditions, and new approaches for therapy taken further in the development pipeline.

Deadline: Tuesday 16th April 2019 at 1700 hrs (CET)

Further information can be found here.

H2020: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health - SC1-BHC-28-2019

Specific ChallengeDespite the general acknowledgement by the scientific community that 'Genetics load the gun but environment pulls the trigger'' when it comes to the causation of major non-communicable diseases (NCDs)there is persistent uncertainty as to the global burden of disease attributable to environmental (including life-style and climatic) factors, including healthcare costs and negative economic impact. Deciphering the human exposome is a novel way of addressing the challenge to improve health and reduce the overall burden of disease. This will require improved knowledge of health risks, including combinations of several risk factors, and the mechanisms by which they affect health at different stages throughout the life course, including exposures in foetal life. Effective preventive action will need to be designed, building on knowledge of various risk factors, including exposure to pollutants in daily life, individual behaviour and the social context, taking into account gender issues.

Developing a Human Exposome Project would present a fundamental shift in looking at health, by moving research away from ‘one exposure, one disease’ understanding to a more complex picture upon which to build solid, cost-effective preventive actions and policies in the future. It would respond to the need for more complete and accurate individual-level exposure data in order to estimate the largely unknown environmental component of NCDs.

ScopeApplicants should take advantage of the last decade's rapid technological advances which have opened up new opportunities to collect, combine and analyse large data sets offering new possibilities to understand the contribution of environmental factors to the global health burden of common chronic diseases. Proposals should use innovative approaches to the systematic and agnostic identification of the most important environmental risk factors for the development of major NCDs across the life course (including in utero), leading to preventive interventions at the individual, group or population level and contribute to sustainable healthcare. Well-designed retrospective epidemiological studies may be included and proposals may envisage the creation of a prospective Europe-wide exposomics cohort and biobank, integrating behavioural, socio-economic factors and clinical records.

The following components should be considered: agnostic evaluation of the role of multiple and unknown exposures; assessment of individual exposure to multiple stressors; sensors that combine external exposure and health data measurements; integration of external exposome data with cross-omics responses and (epi)genetic data; systematic evaluation and simulations of the health impacts; socio-economic modelling and econometric analysis including ethical and sex/gender aspects where relevant; better data mining tools, including advanced statistical analysis of complex data and high-performance/high throughput computing and storage; a long-term host and a single shared data infrastructure, taking into account existing structures and ensuring open access to data generated.

Innovation and connections with industry are expected in the areas of sensor development (external exposome), omics technology and novel biomarker development (internal exposome), bioinformatics, and data processing and management. Proposals are expected to respond to a persistent or long-standing policy/regulatory need where the exposome approach would be useful to solve a scientific issue to underpin better regulation now or in the future (examples: indoor and outdoor air quality, waste, occupational health, noise).

In order to establish an overarching Human Exposome Project, an overall coordination mechanism between the projects funded will be required and will be added at the grant preparation stage to all selected proposals as a common work package. Grants awarded under this topic will be complementary. The respective options of Article 2, Article 31.6 and Article 41.4 of the Model Grant Agreement will be applied.

The Commission considers that a proposal requesting an EU contribution between EUR 8 to 12 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:

  • Innovation in environmental health sciences, in particular for external and internal exposure assessments and data management.

  • Enabling researchers and policy makers to continuously include new knowledge in the policy making processes by using the toolbox to generate data and information.

  • Better prediction of disease risk by acquisition of new knowledge on the influence of external exposures on biological pathways at different life-stages and identification of early signs of health damage caused by environmental factors.

Deadline: Tuesday 16 April 2019 at 1700 hrs (CET)

Further information can be found here.

H2020: Mining big data for early detection of infectious disease threats driven by climate change and other factors - SC1-BHC-13-2019

Specific Challenge:

A range of factors is responsible for the (re-)emergence of infectious disease threats, including antimicrobial resistance, altering the epidemiology and spread of disease in a changing global environment. These include drivers such as climate change and associated environmental impacts, population growth, unplanned urbanisation and high mobility, as well as animal husbandry or intensive farming practices.

At the same time, tools for infectious disease diagnostics and surveillance are evolving rapidly, allowing for ever more accurate diagnosis in ever shorter time. The use of next generation sequencing combined with surveillance data, health registries and societal data from informal/non-traditional sources (e.g. social media) holds promise for improving individual and population health. Current advanced IT technologies offer the opportunity to integrate such big data sets and could enable the rapid and personalised treatment of infected patients, and bolster the detection, tracking and control of infectious disease outbreaks.

ScopeIt is expected that proposals develop:

  1. the technology to allow the pooling, access, analysis and sharing of relevant data, including next generation sequencing;

  2. the innovative bio-informatics and modelling methodologies that enable risk modelling and mapping; and

  3. the analytical tools for early warning, risk assessment and monitoring of (re-)emerging infectious disease threats.

Proposals should be able to demonstrate the feasibility of such extended data mining for the purposes outlined above, as well as its European level added value. The ready-to-use analytical tools and services that are developed should be based on an assessment of the needs of potential end-users in the Member States and on European level, should as far as possible build on and be compatible with existing European initiatives, and should remain available for public use at the end of the project at a reasonable cost.

Proposals should be transdisciplinary and ensure an integrated One Health approach by linking data from a wide range of relevant sources depending on the infectious disease threat. These may include human (e.g. community, hospital or laboratory health services) and animal health surveillance, health registries, microbial and viral genomic data (including next generation sequencing), pathogen resistance data, mapping of vectors, climate and environmental data as well as societal data that are correlates of disease; possible sex and/or gender differences should be taken into account. Solutions for gaps in existing data (addressing both a lack in quality and quantity) should be proposed.

Solutions for interoperability between different data sources should be addressed and integrated. It is expected that quality-controlled data are shared in accordance to the general concepts of the FAIR principles. The use of harmonised protocols in collaboration with other actors is recommended for this purpose. Appropriate regulatory and governance mechanisms need to be foreseen, taking into account different data sharing needs, as well as data privacy and data security aspects for the different types of stakeholders providing and analysing data. The technology and tools developed should be functional outside of outbreaks (i.e. in "peace time"), so that all stakeholders involved develop a routine use of them. At the same time, flexibility is needed to enable adaptation to different outbreak contexts and situations. The proposal shall foresee, in case of public health emergencies, open access to data at the moment it is generated or no later than one month thereafter subject to any safeguards required to protect research participants and patients, in accordance with the relevant options in Article 29.3 of the Model Grant Agreement.

The use of advanced IT technologies like high performance computing, or geo-localisation data are anticipated. The use of European health research (e-)infrastructures such as those included under CORBEL is encouraged where relevant. The successful proposal(s) should foresee to consult with the end-users at both national (e.g. public health institutes) and European (e.g. ECDC, EFSA) level at key milestones of the project's timeline. If more than one proposal is selected, they are expected to collaborate. In addition, coordination will be needed with the selected proposal from the Horizon 2020 call topic SFS-36-2017 on the establishment of a European Joint Programme on One Health.

The Commission considers that proposals requesting a contribution from the EU of between EUR 12-15 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact

  • Strengthened EU preparedness to address threats from (re-)emerging infectious disease threats, by making available the appropriate technology and tools for risk modelling and early threat detection, to support an appropriate public health response.

  • Contribution to the European One Health action plan against antimicrobial resistance.

  • Contribution to the digital transformation of health and care within the context of the EU Digital Single Market.

  • Contribution to achieving Sustainable Development Goal (SDG) 3 and specifically the targets on 1) combating epidemics, and 2) strengthening capacity for early warning and response to health risks.

  • Contribution to achieving of SDG 13 and specifically the targets on 1) integrating climate change measures into national policies, strategies and planning, and 2) improving education, awareness-raising and human and institutional capacity on climate change adaptation, impact reduction and early warning.

Deadline: Tuesday 16th April 2019 at 1700 hrs (CET)

Further information can be found here.

H2020: Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis - SC1-BHC-10-2019

Specific ChallengeWe observe a progressive shift in routine diagnostics, and more particularly in personalised medicine practice, from a growing number of molecular tests to a next generation sequencing approach (NGS). NGS can provide insights on a person’s genetic susceptibility to disease, diagnostic information, and predictive indications about treatment outcome. It also allows to embrace simultaneously different molecular pathways of disease evolution and to identify actionable mutations in a patient for medical decision and further research. In addition, it requires less sample material than multiple tests and therefore reduces risk and inconvenience for patients. However, the introduction of NGS in clinical practice is hampered by its cost, the availability of proper NGS tests, and diagnostic errors resulting from insufficient quality assurance, technological bias and complex interpretation of data.

Scope: The objective is to implement NGS in routine diagnostics for personalised medicine and scale up demand-driven innovation for healthcare systems. This includes organisational, economical, technical and clinical aspects. It should lead to NGS tests, clinically validated procedures (including sex analysis), quality assurance schemes, tools and methods for data collection, management, analysis and interpretation, with a view to assist clinical decision-making and foster medical research and innovation. Transferability and cloud based NGS data analyses should be considered, as appropriate. Input from initiatives like the EJP Cofund on rare diseases and ERNs should be considered when relevant. Ethical issues should be addressed.

For grants awarded under this topic for Pre-Commercial procurement it is expected that results could contribute to European or international standards. Therefore, the respective option of Article 28.2 of the Model Grant Agreement will be applied.

The Commission considers that proposals requesting a contribution from the EU of between EUR 9 and 11 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Proposals of this topic should follow the specific requirements for pre-commercial procurement PCP supported by Horizon 2020 grants as set out in General Annex E of the WP.

Expected Impact:

  • New NGS platforms and use of NGS tests in routine diagnostics for personalised medicine.
  • Accepted new European standards and quality assurance schemes with respect to NGS.
  • Strengthening of implementation of personalised medicine and improved clinical decisions and health outcomes for the benefits of patients.
  • Contribution to the sustainability of healthcare systems.
  • Growth and benefit to the European industry, in particular SMEs.

Deadline: Tuesday 16 April 2019 at 1700 hrs (CET)

Further information can be found here.

 

H2020: Large Scale pilots of personalised & outcome based integrated care - SC1-DTH-11-2019

Specific Challenge: Senior people are statistically at greater risk of cognitive impairment, frailty and multiple chronic health conditions with consequences for their independence, their quality of life (and the one of their families) but also for the sustainability of health and social care systems. There is also increasing evidence that interactions with the environment play an important role in the evolution of the patient's health status and condition. The challenge is now to foster secure, scalable and robust digital solutions for integrated care which will:

  • Ensure a truly personalized delivery of health and social care, whilst supporting outcomes-based significant efficiency gains in health and care delivery.
  • Promote a shift towards outcome-based delivery of integrated (health and social) care, which can be realised in a realistic operational, organisational and financial setting.
  • Ensure trust of users and policy makers with regard to data access, protection and sharing.
  • Design flexible but replicable solutions with a potential for financial sustainability, large scale deployment and further business and job creation opportunities.

Scope: The scope of this topic is to foster the large-scale pilots for deployment of trusted and personalised digital solutions dealing with Integrated Care, with a view to supporting and extending healthy and independent living for older individuals who are facing permanently or temporarily reduced functionality and capabilities. This in turn is expected to contribute to a patient-centred and truly individualized strategy in order to develop trusted, robust and financially sustainable services potentially useable in any Member States and the Digital Single Market, and applicable to a very wide range of patient pathways. These approaches aim to enable people to remain independent as long as possible and prevent hospitalisation.

Expected outcomes are in priority:

  • Efficiency gains in terms of resource utilization and coordination of care.
  • Flexibility and replicability of service delivery patterns to combine personalization and large scale adoption of services with patient and citizen feedback.
  • Ensuring secure and efficient sharing and processing of all data and information involved in the supply chain at each step of data stream: access, protection, sharing, processing and storage.
  • Improvement of quality of life for the patient and his/her family and also of working conditions of all health care and social care providers involved in the supply chain, taking into account multi-disciplinary environment and constraints. Working conditions of professionals should cover in priority: work time management, quality of data/information exchange and multi-disciplinary coordination.

Outcome indicators should contribute to the assessment of the action regarding trust, recruitment, added value for the patient (in terms of quality of life) and cost-efficiency altogether.

  • Recruitment of professionals will be measured by the number of professionals registered as actual used compared with the number of professionals actually registered in the pilot site region.
  • Quality of life should be measured on the basis of commonly used questionnaires (like SF36) but also if required on the basis of specific disease-oriented measurement tools.
  • Measurement of cost-efficiency should be measured on the basis of work time information dedicated to each patient.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:

Proposals should provide measurable progress towards:

  • A common vision of technical prerequisites and framework to ensure users trust with regard to health and social data and information in IT supported environment, in line with existing EU data protection regulation (and if required with EU reflection on platforms).

  • An evidence-based minimum data set on key points of the pathway: Harmonisation, certification, approval labelling or reliable identification of adequate solutions for integrated care.
    • Clerical information: complete definition

    • Clinical information: generic definition.

  • Robust and reliable and replicable business models for IT supported solutions in a truly personalized and multi-disciplinary environment.

Deadline: Wednesday 24 April 2019 at 1700 hrs (CET)

Further information can be found here.

 

H2020: SC1-DTH-01-2019: Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment

Specific Challenge: Currently available methods and strategies for diagnosis and treatment of cancer help clinicians continuously improve quality of care and prevent cancer deaths in the population. Accurate risk assessment, availability of genetic tests, timely diagnosis and effective treatment has created the impression of cancer being a chronic disease that can be cured. However, often rather aggressive treatment, psychological stress (anxiety and depression) can cause physical and psychological problems that may cause long-term after-cure consequences such as similar or other types of cancer, other types of (chronic) diseases and affect the quality of life of a patient. Therefore, the importance of addressing and, if possible, preventing long-term effects of cancer treatment is growing. In addition to patient-reported outcomes such as functional status, symptoms intensity and frequency, multiple domains of well-being and overall satisfaction with life, the use of big data can bring valuable information for monitoring health status and quality of life after the cancer treatment. Big Data can provide new opportunities to define statistical and clinical significance, but present also challenges as it requires specific analytical approaches.

ScopeProposals should focus and deliver on how to better acquire, manage, share, model, process and exploit big data using, if appropriate, high performance computing to effectively monitor health status of individual patients, provide overall actionable insights at the point of care and improve quality of life after the cancer treatment. Relevant solutions include for example systems for determining and monitoring (taking also in account gender differences) the combined effects of cancer treatment, environment, lifestyle and genetics on the quality of life, enabling early identification of effects that can cause development of new medical conditions and/or impair the quality of life. Proposals preferably address relevant health economic issues, use patient reported outcome and experience measures (PROMs and PREMs) and take into account the relevant social aspects of health status and quality of life after cancer treatment. Integrated solutions should include suitable approaches towards security and privacy issues.

Information can be collected from traditional sources of health data (cohorts, comprehensive electronic health records or clinical registries, incl. genetic data, validated biomarkers for remission), from new sources of health data (mobile health apps and wearables) and from sources that are usually created for other purposes such as environmental data.

It is important to assure ethical aspects of data, confidentiality, and anonymity of data transfer and engagement of those who collect / code such data in its analysis and interpretation, in order to avoid misinterpretation and inappropriate conclusions by using proper annotation methodologies of the data. Involvement of those who work within healthcare systems, patients, family and relatives, and the general public is needed.

 

The Commission considers that proposals requesting a contribution from the EU of between EUR 3 and 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts. Participation of SMEs is encouraged.

Expected Impact: The proposal should provide appropriate indicators to measure its progress and specific impact in the following areas:

  • Mapped comprehensive big data in a reachable and manageable way by applying principles for sharing and reusability, creating a network of knowledge by linking translation tools, heterogeneous data sources and biomedical texts for monitoring health status and quality of life after the cancer treatment;
  • Emerging data driven analytics and advanced simulation methods to study causal mechanisms and improve forecasts of ill-health, identification of disease trajectories and relapse;
  • Better and faster means of high quality response to prevent or timely address development of new medical conditions and/or improve the quality of life;
  • Better knowledge for improved patient counselling as well as to improve follow-up of patients;
  • Novel information on health maintenance, onset and course of medical conditions with a view to optimise prevention and treatment;
  • Evidence base for the development of policy strategies for prevention, early diagnosis, therapies as well as addressing health inequalities, support to patient registries at national level;
  • Improved quality of life after cancer treatment, strengthening personal confidence and enhancing employability;
  • Preventative strategies are established which have a real effect of reducing the occurrence of health disorders and co-morbidities associated with cancer treatment.

Deadline: Wednesday 24th April 2019 at 1700 hrs (CET)

Further information can be found here.

 

H2020: SC1-DTH-05-2019 Large scale implementation of digital innovation for health and care in an ageing society

Specific ChallengeAn ageing population is increasing demand-side pressures on public health and social care providers across Europe. These pressures undermine the long-term sustainability of existing models for delivering care services to the ageing population.

The challenge is to scale up outcome-based innovative digital health and care solutions across EU borders through joining up actions in procurement of innovation. Digital health and social care solutions have been tested and have demonstrated success in smaller scale settings. However, despite cooperation initiatives amongst regions through INTERREG programmes [1]or the transfer of innovation schemes of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA)[2], large-scale deployment of digital health and care solutions across EU borders remains limited. There is a lack of collaborative efforts in public purchasing of innovative ICT-based solutions for active and healthy ageing and successfully engaging demand and supply sides in scaling up innovation. This is the case in particular for digital solutions integrating health, social or community care and informal care, IoT enabled independent living solutions[3] that allow the citizens to live safely and independently at home therefore avoiding institutionalisation, or tele-care solutions and tools supporting for self-care and person-centred care. Moreover, take-up of these ICT-based solutions by both public care providers as well as people in need for care is a crucial factor in successfully alleviating the demand-side pressures on public health and care provision. Supporting the public procurement of innovation helps public authorities by aggregating demand and sharing the inherent risks associated to deploying new innovative solutions that can be integrated with existing public health and care provision systems.

ScopeThis topic will contribute to the Digital Single Market Strategy priorities on digital transformation of health and care (notably to the priority on user-centred integrated care), to the Scaling-Up Strategy[4] of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) and will support the EIP on AHA Reference Sites contribution to the Digital Single Market Strategy, notably the priority focusing on user-centred integrated care. The actions supported will target large-scale deployment of digital health and care solutions across different regions in Europe. In line with the priority actions of the EIP on AHA Scaling-up Strategy, the scope of this PPI is to specify, purchase and deploy ICT based solutions (made up of services and ICT products to enable the provision of services) for active and healthy ageing through a common supply and demand side dialogue, which can deliver sustainable, new or improved health and care services promoting patient feedback in which public procurement approaches for innovative solutions lead to improved outcomes. Proposals should:

  • Be driven by clearly identified procurement needs[5] of the participating organisations and building on a deep understanding of the needs of the ageing population, as well as the needs of the relevant health and care providers;
  • Support sustainable deployment of new or improved person-centred and outcome-based services promoting patient feedback by providers involved in the procurement of solutions for digital health and care providers, including networking of inpatient and outpatient care, nursing services and care homes;
  • Contribute to the creation of scalable markets across Europe in innovative solutions for active and healthy ageing;
  • Specify measures that will ensure the sustainability of solutions beyond the lifespan of the proposed project, notably taking into account levels of acceptance with users and professionals as well as health economics considerations.
  • Engage public and/or private procurers from each country participating (at national, regional or local level) that have responsibilities and budget control in the relevant area of care or supply of services;
  • Be based on a complete set of common specifications for end to end services;
  • Demonstrate that the implementation phase will reach "large scale" (i.e. sufficient scale to achieve statistical significance) through region-wide deployment across multiple regions of Europe;
  • Contribute to the use of interoperable solutions based on open platforms and take into account existing best practices and standardisation initiatives;
  • Provide robust safeguards to ensure compliance with ethical standards and privacy protections and take account of the gender dimension;
  • Contribute with good outcome-based practices that are impact measured according to the MAFEIP[6] methodology and can be made available for replication across other regions (e.g. "detailed plans" for larger scale sustainable uptake of innovative solutions for active and healthy ageing, reference material and guidelines, manuals and education materials) through the EIP on AHA innovative practices repository.
  • Contribute to the development of national strategies to stimulate the procurement of digital innovation for health and care services based on the outcomes achieved at national level.

The European Commission considers that proposals requesting a contribution from the EU of between EUR 2 and 5 million would allow this specific challenge to be addressed appropriately through PPI. This does not preclude submission and selection of proposals requesting other amounts.

Proposals of this topic should follow the specific requirements for innovation procurement PPI supported by Horizon 2020 grants as set out in General Annex E of the WP.

Expected impact:The proposal should provide appropriate indicators to measure its progress and specific impact in the following areas:

  • Growing awareness and successful use of public procurement to boost ICT innovation applied to integrated care and active and healthy ageing, implemented across the whole chain of care ultimately benefiting the growing ageing population across Europe;
  • Contribution with data and experiences to regulatory and legislative process development addressing potential barriers to procurement of innovative solutions for active and healthy ageing;
  • Contribution of an open and comprehensive socio-economic evidence base for ICT investments in the field that can support the development of sustainable business models (e.g. cost-benefit analysis, increased efficiency of health and care systems, impact assessments, return on investments, quality of life improvements for users, ethics, safety gain and user satisfaction);
  • Support initiatives on interoperability and standardisation that can contribute to defragmentation of the market for ICT based active and healthy ageing solutions;
  • Creation of economic boundary conditions that can support long-term sustainability of health and care systems and emergence of new business models to develop ICT innovation for active and healthy ageing in Europe;
  • Support forward-looking, concerted public-sector investment strategies that benefit from joint approaches across different regions;
  • Create new opportunities for market uptake and economies of scale for the supply side for ICT based solutions and services for active and healthy ageing in a Digital Single Market for Europe.
  • Contribute to inform policy measures that foster the take-up of ICT solutions for active and healthy ageing.

Deadline: Wednesday 24 April 2019 at 1700 hrs (CET)

Further information can be found here.

Wellcome Trust - Innovator Award

Up to £500,000 available for up to 24 months to support researchers who are transforming great ideas into healthcare innovations that could have a significant impact on human health. The current focus areas are mental health, neurological disorders and neglected tropical diseases (although applications from other areas may be considered).

Deadline: Ongoing

Further information can be found here.

NESTA - Impact Investment Fund

The Fund invests between £150k and £1m in social ventures developing innovations that tackle the major challenges faced by older people, children and communities in the UK. An experienced team of sector experts, venture capitalists, impact investors and evaluators backed by Nesta, provide expertise and guidance, helping companies to grow their reach, demonstrate their impact and become financially sustainable.

Deadline: Ongoing

Further information can be found here.